Меню
Набор скоро начнётся NCT07704294

Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool

— Наблюдательное Optic Neuritis Multiple Sclerosis Neuromyelitis Optica Spectrum Disorder Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: No Intervention: Observational Cohort.
Кому может быть актуально
Состояния в реестре: Optic Neuritis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders. Базовые параметры: от 16 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Великобритания
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool (MS Predictor)

Обзор

The goal of this observational study is to determine whether genetic information, together with clinical information, can be used to improve prediction of future multiple sclerosis (MS) diagnosis after a first-time episode of optic neuritis. The study will also investigate visual outcomes, quality of life, healthcare use, and the acceptability of using genetic information to predict future health outcomes in people with optic neuritis. The main outcomes that we aim to assess are: 1. Incident diagnosis of MS following a first episode of optic neuritis, including time to MS diagnosis. 2. Visual outcomes following optic neuritis, including visual acuity, visual field, and colour vision. 3. Clinical care received following optic neuritis, including specialist review, investigations/tests 4. Health-related and vision-related quality of life. 5. Health economic impacts and healthcare utilisation after experiencing optic neuritis 6. Knowledge, attitudes, and practices/behaviours about using genetic information to predict future MS disease risk. If consented, participants will: 1. Allow researchers to review information from their medical records relating to their optic neuritis diagnosis, investigations, treatments, and outcomes. 2. Be invited to provide a saliva sample for genetic analysis. 3. Complete questionnaires about their lifestyle/risk factors, quality of life, and views on genetic risk prediction. 4. Allow researchers to track long-term health outcomes using information from their NHS records

Вмешательства

  • Другое No Intervention: Observational Cohort
    Not applicable - No intervention as this is an observation study

Первичные конечные точки

  • Incident Multiple Sclerosis Diagnosis Following a First Episode of Optic Neuritis [Срок оценки: Extracted from retrospective record at baseline, and reviewed before study end to capture any new events occurring during the 12 month study period.]
Вторичные конечные точки (12)
  • Visual Acuity (LogMAR) [Срок оценки: From the date of first optic neuritis diagnosis until the last available follow-up assessment (up to 15 years).]
  • Visual Field Mean Deviation (dB) [Срок оценки: From the date of first optic neuritis diagnosis until the last available follow-up assessment (up to 15 years).]
  • Colour Vision (Number of Ishihara Plates Correctly Identified) [Срок оценки: From the date of first optic neuritis diagnosis until the last available follow-up assessment (up to 15 years).]
  • Number of Healthcare Consultations Following Optic Neuritis Diagnosis [Срок оценки: 12 months]
  • Number of Investigations Performed Following Optic Neuritis Diagnosis [Срок оценки: 12 months]
  • Time to Diagnostic Investigations Following Optic Neuritis Diagnosis (Days) [Срок оценки: 12 months]
  • Time to Treatment Following Optic Neuritis Diagnosis (Days) [Срок оценки: 12 months]
  • Number of Treatment Episodes Following Optic Neuritis Diagnosis [Срок оценки: 12 months]
  • Health-Related Quality of Life (EuroQol 5-Dimension 5-Level Questionnaire [EQ-5D-5L]) [Срок оценки: Measured at baseline recruitment and repeated 3-12 months later]
  • Vision-Related Quality of Life (National Eye Institute Visual Function Questionnaire-25 [NEI-VFQ-25]) [Срок оценки: Baseline and repeated 3-12 months later]
  • Optic Neuritis-Related Quality of Life (Semi-Structured Questionnaire) [Срок оценки: Measured at baseline recruitment and repeated 3-12 months later]
  • Fatigue (Patient-Reported Outcomes Measurement Information System [PROMIS] Fatigue 6a) [Срок оценки: Baseline recruitment and repeated once 3-12 months later]

Критерии участия

Критерии включения

  • Aged 16 years and above at time of consent
  • Previous episode of optic neuritis diagnosed at one of the participating sites

Критерии исключения

  • Patients for whom data relating to the first episode of ON are not available in the medical record at a participating site
  • Children <16 years at the time of recruitment

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Великобритания · 3 центра
  • Moorfields Eye Hospital NHS Foundation Trust — London
  • Guy's and St Thomas' NHS Foundation Trust — London
  • King's College Hospital NHS Foundation Trust — London

Публикации

  • Panthagani J, O'Donovan C, Aiyegbusi OL, Liu X, Bayliss S, Calvert M, Pesudovs K, Denniston AK, Moore DJ, Braithwaite T. Evaluating patient-reported outcome measures (PROMs) for future clinical trials in adult patients with optic neuritis. Eye (Lond). 2023 Oct;37(15):3097-3107. doi: 10.1038/s41433-023-02478-z. Epub 2023 Mar 17. PMID 36932161
  • Braithwaite T, Wiegerinck N, Petzold A, Denniston A. Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives. Ophthalmol Ther. 2020 Jun;9(2):215-220. doi: 10.1007/s40123-020-00247-9. Epub 2020 Mar 21. PMID 32200476
  • Laviers H, Petzold A, Braithwaite T. How far should I manage acute optic neuritis as an ophthalmologist? A United Kingdom perspective. Eye (Lond). 2024 Aug;38(12):2238-2245. doi: 10.1038/s41433-024-03164-4. Epub 2024 Jun 12. PMID 38867071
  • Petzold A, Braithwaite T, van Oosten BW, Balk L, Martinez-Lapiscina EH, Wheeler R, Wiegerinck N, Waters C, Plant GT. Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):9-14. doi: 10.1136/jnnp-2019-321653. Epub 2019 Nov 18. No abstract available. PMID 31740484
  • Braithwaite T, Subramanian A, Petzold A, Galloway J, Adderley NJ, Mollan SP, Plant GT, Nirantharakumar K, Denniston AK. Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. JAMA Neurol. 2020 Dec 1;77(12):1514-1523. doi: 10.1001/jamaneurol.2020.3502. PMID 33017023
  • Loginovic P, Wang F, Li J, Ferrat L, Mirshahi UL, Rao HS, Petzold A, Tyrrell J, Green HD, Weedon MN, Ganna A, Tuomi T, Carey DJ; UKBB Eye & Vision Consortium; FinnGen; Geisinger-Regeneron DiscovEHR Collaboration; Oram RA, Braithwaite T. Applying a genetic risk score model to enhance prediction of future multiple sclerosis diagnosis at first presentation with optic neuritis. Nat Commun. 2024 Feb 28 PMID 38418465

Идентификаторы

NCT: NCT07704294 · 352834 · 222

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗